{"blog": [], "keywords": [{"value": "Valeant Pharmaceuticals International Inc", "name": "organizations", "rank": "1", "is_major": "Y"}, {"value": "Company Reports", "name": "subject", "rank": "2", "is_major": "N"}, {"value": "Pearson, John Michael (1959- )", "name": "persons", "rank": "3", "is_major": "N"}], "web_url": "http://www.nytimes.com/2016/03/06/business/a-troubling-timeline-at-valeant.html", "document_type": "article", "byline": {"person": [{"lastname": "MORGENSON", "firstname": "Gretchen", "role": "reported", "organization": "", "rank": 1}], "original": "By GRETCHEN MORGENSON"}, "type_of_material": "News", "multimedia": [{"url": "images/2016/03/06/business/06gret1/06gret1-thumbWide-v3.jpg", "legacy": {"wide": "images/2016/03/06/business/06gret1/06gret1-thumbWide-v3.jpg", "wideheight": "126", "widewidth": "190"}, "subtype": "wide", "type": "image", "width": 190, "height": 126}, {"url": "images/2016/03/06/business/06gret1/06gret1-articleLarge-v3.jpg", "legacy": {"xlarge": "images/2016/03/06/business/06gret1/06gret1-articleLarge-v3.jpg", "xlargeheight": "527", "xlargewidth": "600"}, "subtype": "xlarge", "type": "image", "width": 600, "height": 527}, {"url": "images/2016/03/06/business/06gret1/06gret1-thumbStandard-v3.jpg", "legacy": {"thumbnail": "images/2016/03/06/business/06gret1/06gret1-thumbStandard-v3.jpg", "thumbnailheight": "75", "thumbnailwidth": "75"}, "subtype": "thumbnail", "type": "image", "width": 75, "height": 75}], "section_name": "Business Day", "word_count": "999", "source": "The New York Times", "subsection_name": null, "lead_paragraph": "A growing trickle of head-scratching news adds to gaps in Valeant Pharmaceuticals\u2019 financial disclosures, despite attempts to burnish results.", "pub_date": "2016-03-06T00:00:00Z", "news_desk": "SundayBusiness", "headline": {"kicker": "Fair Game", "print_headline": "A Troubling Blooper Reel at Valeant", "main": "A Troubling Timeline at Valeant", "content_kicker": "Fair Game"}, "print_page": "1", "snippet": "A growing trickle of head-scratching news adds to gaps in Valeant Pharmaceuticals\u2019 financial disclosures, despite attempts to burnish results.", "_id": "56d9cd9c38f0d83eee09783c", "slideshow_credits": null, "abstract": "Gretchen Morgenson Fair Game column questions why Wall Street analysts continue to support Valeant Pharmaceuticals International; notes company misstated earnings and tried to keep investors in dark about SEC investigation. "}